The product is intended for the removal of foreign material such as microorganisms and debris following dermal procedures.
“Within my practice I utilize the Microcyn Technology post-procedure and have been most impressed with its ability to accelerate the healing process, manage post-procedure symptoms and protect against secondary infections,” said Michael Gold, MD, a board-certified dermatologist and cosmetic surgeon.
Etaluma, Calif.-based Oculus plans to launch the dermatology product in the U.S. in March 2017.
More articles on supply chain:
Hillary Clinton calls on Mylan to lower EpiPen prices
Medical device, drug recalls soar in Q2
Medical device giant Medtronic takes over HeartWare for $1.1B
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.